학술논문
S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE‐AGENT CONTINUATION IN PATIENTS AGED 18‐75 YEARS WITH NEWLY DIAGNOSED FLT3‐ITD+ AML.
Document Type
Article
Author
Source
HemaSphere; 2022 Supplement 3, Vol. 6, p1-2, 2p
Subject
Language
ISSN
25729241